Menu

David CHIRON

NANTES

En résumé

Pas de description

Entreprises

  • Inserm U892 - PhD

    2013 - maintenant
  • Weill Cornell Medical College - Postdoctoral Associate

    2011 - 2013 Publications :
    1. Chiron D, Di Liberto M, Martin P, Huang X, Sharman J, Blecua P, Mathew S, Vijay P, Eng K, Ali S, Johnson A, Chang B, Ely S, Elemento O, Mason CE, Leonard JP, Chen-Kiang S. (2014) Cell Cycle Reprogramming for PI3K Inhibition Overrides Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma.
    Cancer Discovery. In Press

    2. Chiron D, Martin P, Di Liberto M, Huang X, Ely S, Lannutti BJ, Leonard JP, Mason CE, Chen-Kiang S. (2013) Induction of prolonged early G 1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kdelta inhibition through PIK3IP1. Cell Cycle.15;12(12):1892-900.

    3. Chiron D, Maïga S, Descamps G, Moreau P, Le Gouill S, Bataille R, Amiot M, Pellat-Deceunynck C. Autocrine IGF1 and SCF but not IL6 support self-renewal of human myeloma cells. Blood Cancer Journal 2013; In press

    4. Surget S, Chiron D, Gomez-Bougie P, Descamps G, Ménoret E, Bataille R, Moreau P, Le Gouill S, Amiot
    M, Pellat-Deceunynck C. (2012) Cell Death via DR5, but not DR4, is regulated by p53 in myeloma cells.
    Cancer Res. 72: 4562-73.

    5. Chiron D, Maïga S, Descamps G, Moreau P, Le Gouill S, Marionneau S, Ouiller T, Moreaux J, Klein B,
    Bataille R, Amiot M, Pellat-Deceunynck C. (2012) Critical role of the NOTCH ligand JAG2 in self-renewal
    of myeloma cells. Blood Cells Mol Dis. 48:247-53

    6. Jego G, Chiron D, Berthenet K, Pellat-Deceunynck C. (2012) Modulation of normal and malignant plasma
    cells function by toll-like receptors. (review) Front Biosci (Elite Ed). 4:2289-301.

    7. Chiron D, Surget S, Maiga S, Bataille R, Moreau P, Le Gouill S, Amiot M, Pellat-Deceunynck C. (2012) The peripheral CD138+ population but not the CD138- populations contains myeloma clonogenic cells in plasma cell leukemia patients. Br. J of Hematology. 156:679-83

    8. Geffroy-Luseau A, Chiron D, Descamps G, Jégo G, Amiot M, Pellat-Deceunynck C. (2011) TLR9 Ligand
    Induces the Generation of CD20+ Plasmablasts and Plasma Cells from CD27+ Memory B-Cells (2011)
    Front Immunol. 2: 83 doi: 10.3389/fimmu.2011.00083

    9. Chiron D, Jego G, Pellat-Deceunynck C. (2010) Toll-like receptors: Expression and involvement in Multiple
    Myeloma. (review) Leukemia Research. 34:1545-50

    10. Chiron D, Pellat-Deceunynck C, Maillasson M, Bataille R, Jego G. (2009) Phosphorothioate-modified
    TLR9 ligands protect cancer cells against TRAIL-induced apoptosis. J. Immunol. 183:4371-4377.

    11. Chiron D, Pellat-Deceunynck C, Amiot M, Bataille R, Jego G. (2009) TLR3 ligand induces NF-{kappa}B
    activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. J. Immunol.
    182:4471-4478.

    12. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. (2008) Toll-like receptors: lessons
    to learn from normal and malignant human B cells. (review) Blood. 112:2205-2213.
  • INSERM U892 - Doctorant

    2007 - 2011

Formations

Réseau